Manager, Medical Drug Management and Customer Initiatives, BCBS Michigan.
Data Science Manager, Cigna Health Corporation.
J Manag Care Spec Pharm. 2020 Apr;26(4):375-381. doi: 10.18553/jmcp.2020.19372. Epub 2020 Mar 4.
Research agendas play valuable roles in clearly identifying high-priority topics that reflect potential to improve health care quality. The purpose of this report is to present work completed by the Academy of Managed Care Pharmacy (AMCP) and AMCP Foundation Joint Research Committee. This committee set forth to develop a research agenda for our 2 organizations that focuses on critical evidence needs in managed care pharmacy. This document reviews results from 2 surveys that were conducted to better understand unmet research needs within managed care pharmacy and to inform professional efforts of managed care pharmacists. The first survey collected qualitative data from key opinion leaders (KOLs) regarding the top evidentiary gaps in managed care pharmacy and barriers to closing those gaps. The second survey was sent to AMCP members and AMCP Foundation stakeholders, used a mixed methods quantitative-qualitative design, and incorporated concepts from initial KOL responses. The key outcome from these proceedings is the research agenda, which identifies and prioritizes 4 evidentiary gaps in managed care pharmacy: (1) real-world evidence to inform managed care pharmacy decision making, (2) value-based models in managed care pharmacy to address total cost of care, (3) impact of benefit design or utilization management strategies on patient outcomes, and (4) impact of direct patient care services provided by managed care pharmacy on patient outcomes. The agenda was intended to be broad and will evolve over time. AMCP and the AMCP Foundation hope that this research agenda inspires the AMCP membership, researchers, and funding agencies to close these gaps in knowledge and understanding. DISCLOSURES: Chairs and members of the Joint Research Committee oversaw and conducted the work outlined in this report with the support of AMCP and the AMCP Foundation. No outside funding was received. Gembarski, Couto, Wilson, and Eichenbrenner declare no conflicts of interest, real or apparent, with any product or service mentioned in this report. Gembarski is employed by BCBS Michigan; Couto is employed by Cigna; Wilson is employed by HealthCore, a wholly owned subsidiary of Anthem; and Eichenbrenner is employed by the AMCP Foundation.
研究议程在明确确定反映改善医疗保健质量潜力的高优先级主题方面发挥着宝贵的作用。本报告的目的是介绍由管理式医疗药房协会（AMCP）和 AMCP 基金会联合研究委员会完成的工作。该委员会着手为我们的 2 个组织制定管理式医疗药房研究议程，重点关注管理式医疗药房的关键证据需求。本文档回顾了为更好地了解管理式医疗药房中未满足的研究需求并为管理式医疗药剂师的专业工作提供信息而进行的 2 项调查的结果。第一项调查从关键意见领袖（KOL）那里收集了有关管理式医疗药房中最重要的证据差距以及缩小这些差距的障碍的定性数据。第二项调查发送给了 AMCP 成员和 AMCP 基金会利益相关者，采用了混合方法定量定性设计，并纳入了初始 KOL 回复中的概念。这些程序的主要结果是研究议程，该议程确定并优先考虑了管理式医疗药房中的 4 个证据差距：（1）真实世界的证据以告知管理式医疗药房的决策，（2）管理式医疗药房中的基于价值的模型以解决总成本，（3）受益设计或利用管理策略对患者结果的影响，以及（4）管理式医疗药房提供的直接患者护理服务对患者结果的影响。该议程旨在广泛，并且会随着时间的推移而不断发展。AMCP 和 AMCP 基金会希望该研究议程能够激发 AMCP 成员，研究人员和资助机构来弥补这些知识和理解上的差距。披露：联合研究委员会的主席和成员在 AMCP 和 AMCP 基金会的支持下监督和开展了本报告中概述的工作。没有收到外部资金。Gembarski、Couto、Wilson 和 Eichenbrenner 均声明与本报告中提到的任何产品或服务均无实际或明显的利益冲突。Gembarski 受雇于蓝十字蓝盾密歇根；Couto 受雇于信诺；Wilson 受雇于 HealthCore，Anthem 的全资子公司；Eichenbrenner 受雇于 AMCP 基金会。
